Overexpression of Lgr5 Correlates with Resistance to 5-FU-based Chemotherapy in Colorectal Cancer

Overview

Journal Int J Colorectal Dis

Specialties Gastroenterology
General Surgery

Date 2013 Jun 21

PMID 23784051

Citations 49

Authors

Hung-Chih Hsu

Yi-Shiuan Liu

Kai-Chi Tseng

Cheng-Lung Hsu

Ying Liang

Tsai-Sheng Yang

Jinn-Shiun Chen

Rei-Ping Tang

Shu-Jen Chen

Hua-Chien Chen

Affiliations

Soon will be listed here.

Abstract

Background: The leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) is an adult intestinal stem cell marker frequently detected in human colorectal cancers (CRCs). However, the value of Lgr5 level in CRC prognosis and treatment prediction has not been well characterized.

Methods: We examined Lgr5 expression in 384 formalin-fixed paraffin-embedded CRC specimens from 296 CRC patients, including 64 patients treated with 5-fluorouracil (5-FU)-based chemotherapy. The effects of Lgr5 on cell proliferation, survival, and drug resistance were examined in cultured CRC cells.

Results: Elevated expression of Lgr5 was observed in CRC tissues, and Lgr5 protein levels were significantly correlated with an advanced American Joint Committee on Cancer stage (P < 0.001), T stage (P < 0.001), N stage (P < 0.001), and distant metastasis (P < 0.001). High expression levels of Lgr5 were significantly associated with shorter disease-free survival (P < 0.001) and shorter cancer-specific survival (P = 0.007) in CRC patients. Among the chemotherapy-treated subgroups, patients with low Lgr5 level showed a better response rate (65 %) than patients with high Lgr5 level (37 %) towards 5-FU-based treatment (P = 0.025). In cultured CRC cell lines, knocking down Lgr5 suppressed cell proliferation and colony formation ability, while it enhanced apoptosis and rendered cells more sensitive to chemotherapeutic agents. In contrast, overexpression of Lgr5 increased cell proliferation and enhanced chemoresistance.

Conclusion: These results suggest that elevated Lgr5 level is associated with CRC progression and treatment response and has the potential to serve as a therapeutic target in CRC patients.

Citing Articles

LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance.

Wang W, Lokman N, Barry S, Oehler M, Ricciardelli C Cancer Metastasis Rev. 2025; 44(1):23.

PMID: 39821694 PMC: 11742290. DOI: 10.1007/s10555-024-10239-x.

Veratridine, a plant-derived alkaloid, suppresses the hyperactive Rictor-mTORC2 pathway: a new targeted therapy for primary and metastatic colorectal cancer.

Eikanger M, Sane S, Schraufnagel K, Slunecka J, Potts R, Freeling J Res Sq. 2024; .

PMID: 39502780 PMC: 11537347. DOI: 10.21203/rs.3.rs-5199838/v1.

Clinical Implications and Prognostic Value of Leucine-Rich G Protein-Coupled Receptor 5 Expression as A Cancer Stem Cell Marker in Malignancies: A Systematic Review and Meta-Analysis.

Ghobakhloo S, Khoshhali M, Vatandoost N, Jafarpour S, Niazmand A, Nedaeinia R Cell J. 2024; 26(1):1-12.

PMID: 38351725 PMC: 10864775. DOI: 10.22074/cellj.2023.2010157.1396.

STAT2 Controls Colorectal Tumorigenesis and Resistance to Anti-Cancer Drugs.

Chiriac M, Hracsko Z, Becker C, Neurath M Cancers (Basel). 2023; 15(22).

PMID: 38001683 PMC: 10670206. DOI: 10.3390/cancers15225423.

Peristalsis-Associated Mechanotransduction Drives Malignant Progression of Colorectal Cancer.

Clevenger A, McFarlin M, Collier C, Sheshadri V, Madyastha A, Gorley J Cell Mol Bioeng. 2023; 16(4):261-281.

PMID: 37811008 PMC: 10550901. DOI: 10.1007/s12195-023-00776-w.

References

Becker L, Huang Q, Mashimo H . Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma. Dis Esophagus. 2009; 23(2):168-74. DOI: 10.1111/j.1442-2050.2009.00979.x. View

Wu X, Xi H, Chen L . Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol. 2012; 10:244. PMC: 3506563. DOI: 10.1186/1477-7819-10-244. View

Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, Kenetaka K, Asaka M . Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology. 2003; 37(3):528-33. DOI: 10.1053/jhep.2003.50029. View

Cunningham D, Atkin W, Lenz H, Lynch H, Minsky B, Nordlinger B . Colorectal cancer. Lancet. 2010; 375(9719):1030-47. DOI: 10.1016/S0140-6736(10)60353-4. View

Visvader J, Lindeman G . Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012; 10(6):717-728. DOI: 10.1016/j.stem.2012.05.007. View

May R, Sureban S, Hoang N, Riehl T, Lightfoot S, Ramanujam R . Doublecortin and CaM kinase-like-1 and leucine-rich-repeat-containing G-protein-coupled receptor mark quiescent and cycling intestinal stem cells, respectively. Stem Cells. 2009; 27(10):2571-9. PMC: 3049723. DOI: 10.1002/stem.193. View

Hochster H, Hart L, Ramanathan R, Childs B, Hainsworth J, Cohn A . Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008; 26(21):3523-9. DOI: 10.1200/JCO.2007.15.4138. View

Vaiopoulos A, Kostakis I, Koutsilieris M, Papavassiliou A . Colorectal cancer stem cells. Stem Cells. 2012; 30(3):363-71. DOI: 10.1002/stem.1031. View

Zeki S, Graham T, Wright N . Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011; 8(2):90-100. DOI: 10.1038/nrgastro.2010.211. View

10.

Takahashi H, Ishii H, Nishida N, Takemasa I, Mizushima T, Ikeda M . Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol. 2010; 18(4):1166-74. DOI: 10.1245/s10434-010-1373-9. View

11.

Weitz J, Koch M, Debus J, Hohler T, Galle P, Buchler M . Colorectal cancer. Lancet. 2005; 365(9454):153-65. DOI: 10.1016/S0140-6736(05)17706-X. View

12.

Hsu S, Liang S, Hsueh A . Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region. Mol Endocrinol. 1998; 12(12):1830-45. DOI: 10.1210/mend.12.12.0211. View

13.

Barker N, Ridgway R, van Es J, van de Wetering M, Begthel H, van den Born M . Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2008; 457(7229):608-11. DOI: 10.1038/nature07602. View

14.

Ricci-Vitiani L, Lombardi D, Pilozzi E, Biffoni M, Todaro M, Peschle C . Identification and expansion of human colon-cancer-initiating cells. Nature. 2006; 445(7123):111-5. DOI: 10.1038/nature05384. View

15.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

16.

de Sousa E Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong J . Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell. 2011; 9(5):476-85. DOI: 10.1016/j.stem.2011.10.008. View

17.

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2003; 22(2):229-37. DOI: 10.1200/JCO.2004.05.113. View

18.

Douillard J, Hoff P, Skillings J, Eisenberg P, Davidson N, Harper P . Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002; 20(17):3605-16. DOI: 10.1200/JCO.2002.04.123. View

19.

Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T . Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011; 17(21):6934-43. DOI: 10.1158/1078-0432.CCR-11-1180. View

20.

Hoff P, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M . Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001; 19(8):2282-92. DOI: 10.1200/JCO.2001.19.8.2282. View